A detailed history of New York State Common Retirement Fund transactions in Nuvalent, Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 16,971 shares of NUVL stock, worth $1.46 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,971
Previous 19,466 12.82%
Holding current value
$1.46 Million
Previous $1.99 Million 33.3%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 31, 2025

SELL
$77.87 - $104.93 $194,285 - $261,800
-2,495 Reduced 12.82%
16,971 $1.33 Million
Q3 2024

Oct 28, 2024

SELL
$67.44 - $112.17 $622,808 - $1.04 Million
-9,235 Reduced 32.18%
19,466 $1.99 Million
Q2 2024

Jul 31, 2024

BUY
$62.76 - $81.61 $117,737 - $153,100
1,876 Added 6.99%
28,701 $2.18 Million
Q1 2024

May 07, 2024

BUY
$72.35 - $88.99 $337,946 - $415,672
4,671 Added 21.08%
26,825 $2.01 Million
Q4 2023

Feb 01, 2024

BUY
$42.42 - $80.28 $82,591 - $156,305
1,947 Added 9.64%
22,154 $1.63 Million
Q3 2023

Nov 07, 2023

BUY
$39.12 - $49.85 $262,651 - $334,692
6,714 Added 49.76%
20,207 $929,000
Q2 2023

Aug 07, 2023

SELL
$23.58 - $44.68 $49,470 - $93,738
-2,098 Reduced 13.46%
13,493 $569,000
Q1 2023

May 02, 2023

BUY
$25.42 - $33.52 $66,702 - $87,956
2,624 Added 20.24%
15,591 $407,000
Q4 2022

Jan 30, 2023

SELL
$18.46 - $36.37 $36 - $72
-2 Reduced 0.02%
12,967 $386,000
Q3 2022

Nov 08, 2022

BUY
$13.55 - $19.92 $392 - $577
29 Added 0.22%
12,969 $252,000
Q2 2022

Aug 04, 2022

BUY
$7.4 - $15.07 $133 - $271
18 Added 0.14%
12,940 $175,000
Q1 2022

May 05, 2022

BUY
$11.65 - $19.57 $59,648 - $100,198
5,120 Added 65.62%
12,922 $179,000
Q4 2021

Feb 02, 2022

BUY
$18.01 - $30.1 $140,514 - $234,840
7,802 New
7,802 $149,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.69B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.